A sample of Oxymetholone 50 mg tablets, manufactured by Qingdao Sigma Chemicals (QSC), was independently procured and submitted for laboratory analysis by an individual consumer, MissedArmDay66. The testing was fully funded by the submitter, ensuring no financial conflicts of interest from the manufacturer. The purpose of the analysis was to verify the product’s composition and assess the accuracy of the labeled dosage.
The laboratory results confirmed that the tested Oxymetholone tablets contained 53.06 mg, 54.03 mg, and 57.18 mg per tablet, indicating an overdose compared to the stated claim of 50 mg per tablet. This suggests inconsistency in the manufacturing process, as the measured values show a variance of 6-14% above the intended concentration.
While an overdose of the active ingredient may not necessarily be problematic, fluctuations in potency can introduce risks related to unintended dosing variations. These results emphasize the necessity of independent testing to verify the quality, accuracy, and safety of such products.
Detailed Report
Product Overview
- Manufacturer: Qingdao Sigma Chemicals (QSC)
- Product Name: Oxymetholone
- Batch Number: Unknown
- Expiration Date: Not Provided
- Delivery Method: Oral (Tablet)
- Specification: 50 mg/tablet
Sample Acquisition and Testing
- Task Number: #56001
- Testing Ordered: 06 JAN 2025
- Sample Received: 15 JAN 2025
- Analysis Conducted By: Janoshik
- Product Submitted By: MissedArmDay66 (Individual)
- Analysis Paid For By: MissedArmDay66 (Individual)
Testing Results
| Component/Test | Specification (Label Claim) | Measured Concentration | Compliance/Remarks |
|---|---|---|---|
| Oxymetholone | 50 mg/tablet | 53.06 mg, 54.03 mg, 57.18 mg | Overdosed (6-14% above label claim) |
Verification Details
- Verification URL: https://janoshik.com/tests/56001_1BRBWNJ462ZD
- Originally Published: https://thinksteroids.com/community/posts/3425945/
Evaluation of Independent Testing
The presence of the declared active ingredient in the tested sample was confirmed. However, the results indicate higher than labeled dosages, with concentration levels exceeding the 50 mg claim by up to 14%. This highlights potential inconsistencies in the manufacturing process and raises concerns about batch-to-batch reliability.
While a slight overdose of the active ingredient may not be inherently harmful, precise dosing is crucial for users managing intake and minimizing potential side effects. Fluctuations in potency can lead to unexpected effects, reinforcing the need for stringent quality control from the manufacturer.
Since this sample was independently procured by an individual rather than being provided by the manufacturer, the credibility of the findings is stronger compared to manufacturer-funded testing, which can sometimes be biased due to selective sample submissions.
Conclusion
The analysis of Qingdao Sigma Chemicals Oxymetholone 50 mg tablets revealed that the product contained more active ingredient than declared, with measured values exceeding the label claim by 6-14%. While this confirms the presence of the intended compound, it also raises concerns about manufacturing consistency and dosage precision.
Independent third-party testing remains essential for ensuring product quality and consumer safety. Users should exercise caution with overdosed products, as inconsistent potency can lead to unintended dosing variations. Consumers are advised to cross-reference findings with additional independent testing whenever possible.
Disclaimer
This report is published for educational and harm reduction purposes. Independent testing provides valuable insights; however, these findings pertain solely to the analyzed batch and may not represent the entire product line. Consumers are encouraged to critically assess this information alongside additional independent analyses.
